The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C

Cancer Research

Volumn 61, Issue 22, 2001, Pages 8203-8210

  Tenzer, Angela ^a,d   Zingg, Daniel ^a,d   Rocha, Sonia ^a   Glanzmann, Christoph ^a   Bodis, Stephan ^a   Pruschy, Martin ^a   Fabbro, Doriano ^b   Hemmings, Brian ^c   Schubiger, P August ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MIDOSTAURIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C INHIBITOR; RADIOSENSITIZING AGENT; STAUROSPORINE; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; AKT1 PROTEIN, RAT; CHROMONE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; GLYCOGEN SYNTHESIS; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DOWN REGULATION; TARGET CELL; ANIMAL; CELL CULTURE; CELL LINE; CELL TRANSFORMATION; DOWN REGULATION; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; ONCOGENE RAS; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CHROMONES; DOWN-REGULATION; ENZYME INHIBITORS; GENES, RAS; HUMANS; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0035889243     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Mechanism of activation and function of protein kinase B
2. Mechanisms and consequences of activation of protein kinase B/Akt
3. Akt is a direct target of the phosphatidylinositol 3-kinase
4. Direct regulation of Akt protooncogene product by phosphatidylinositol-3, 4-bisphosphate
5. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
6. Mechanism of activation of protein kinase B by insulin and IGF-1
7. Domain swapping used to investigate the mechanism of protein kinase B regulation by 3-phosphoinositide-dependent protein kinase I and Ser473 kinase
8. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site
9. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
10. Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
11. Stripes defeat the Fermi liquid
12. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element
13. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions
14. PI3-K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis
15. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress
16. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis
17. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide
18. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473
19. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
20. Cyclic nucleotides suppress tumor necrosis factor α-mediated apoptosis by inhibiting caspase activation and cytochrome c release in primary hepatocytes via a mechanism independent of Akt activation
21. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis
22. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
23. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
24. Loss of PTEN facilitates HIF-1-mediated gene expression
25. A specific inhibitor of phosphaticylinositol 3-kinase 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
26. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
27. Activation and phosphorylation of a pleckstrin domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors
28. cAMP stimulates protein kinase B in a wortmannin-insensitive manner
29. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
30. The ras radiation resistance pathway
31. Protein kinase C-α overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal
32. Stimulation of protein kinase C modulates insulin-like growth factor-1-induced Akt activation in PC12 cells
33. Protein kinase C is a negative regulator of protein kinase B activity
34. Protein kinase C inhibitor and irradiation-induced apoptosis: Relevance of the cytochrome c-mediated caspase-9 death pathway
35. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the cPKC-specific inhibitor PKC412
36. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
37. PKC412-a protein kinase inhibitor with a broad therapeutic potential
38. p53 status and the efficacy of cancer therapy in vivo
39. Role of translocation in the activation and function of protein kinase B
40. Production of high-titer helper-free retroviruses by transient transfection
41. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
42. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation
43. Apafl is required for mitochondrial pathways of apoptosis and brain development
44. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
45. p53 inhibits α6β4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB
46. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling
47. Protein kinase CβII activation by 1-β-D-arabinofuranosyleytosine is antagonistic to stimulation of apoptosis and Bcl-2α down-regulation
48. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway
49. Insulin-stimulated protein kinase B phosphorylation on Ser473 is independent of its activity and occurs through a staurosporine-insensitive kinase
50. Akt is activated in response to an apoptotic signal
51. Homogeneous purification of human recombinant GST-Akt/PKB from SF9 cells
52. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine
53. PI3-kinase is an essential antiapoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS
54. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1
55. Cellular survival: A play in three Akts
56. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9
57. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
58. Key targets for the execution of radiation-induced tumor cell apoptosis: The role of p53 and caspases